Multaq Linked to Lung Disease and Pulmonary Toxicity

In September 2012, the US FDA approved some label changes for Multaq, including certain types of lung disease and pulmonary toxicity as serious side effects of the drug. Multaq (Dronedarone) is a drug manufactured by Sanofi and used by patients who had recently experienced heart issues like atrial fibrillation (a type of abnormal heart rhythm) or atrial flutters. It was approved by the FDA in 2009. In December 2011, the FDA issued a warning indicating that health care professionals should not prescribe Multaq to patients with permanent atrial fibrillation because of “increased risk of death or serious cardiovascular events”. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Multaq severe adverse events. [http://www.attorneyone.com/multaq/

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Multaq: severe adverse events threat

Multaq: severe adverse events threat

cases of interstitial lung disease including pneumonitis and pulmonary fibrosis have been reported in patients treated with Multaq

San Diego, CA (PRWEB) October 31, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who filed a Multaq Lawsuit. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

In September 2012, the US FDA approved some label changes for Multaq, including certain types of lung disease and pulmonary toxicity as serious side effects of the drug. Multaq (Dronedarone) is a drug manufactured by Sanofi and used by patients who had recently experienced heart issues like atrial fibrillation (a type of abnormal heart rhythm) or atrial flutters. It was approved by the FDA in 2009. According to the FDA, cases of interstitial lung disease including pneumonitis and pulmonary fibrosis have been reported in patients treated with Multaq in the post-marketing setting.

In December 2011, the FDA issued a warning indicating that health care professionals should not prescribe Multaq to patients with permanent atrial fibrillation because of “increased risk of death or serious cardiovascular events”.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe adverse events from Multaq, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Multaq remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

In January 2011, the FDA issued a warning about cases of rare, but severe liver injury, including two cases of acute liver failure leading to liver transplant in patients treated with Multaq.

AttorneyOne.com has further information on Multaq lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/10/prweb10059629.htm.